Doctor talks groundbreaking leap in fighting lung disease

JACKSON, Tenn. — One company is spotlighting a historic step in the fight against chronic respiratory disease.

SMSbiotech specializes in regenerative medicine and has developed a groundbreaking human stem cell known as the small mobile stem cell, or SMS cell.

Recently, the company launched its first human clinical trial for COPD after more than a decade of research.

Current treatments manage symptoms, but SMSbiotech’s therapy targets damaged lung tissue — the root of the cause.

“These cells have never been used in medicine,” said Dr. Abdulkader Rahmo. “They could open up a new horizon for these applications in chronic diseases. There is a lot to be hoped for for people who suffer from diseases that are so widespread – with COPD we are talking 400 million people worldwide.”

SMS cells stimulate the body’s own stem cells to regenerate tissue, making them safer and more natural than other cell therapies.

To learn more about SMSbiotech and the new chapter in regenerative medicine, click here.

For local news, click here.